title: Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Southwest Oncology Group.
abstract: OBJECTIVE
  Based upon the hypothesis that prolonged exposure to the S-Phase specific agent topotecan would be more efficacious in the treatment of soft tissue sarcomas than a conventional 5-day schedule of the drug, the Southwest Oncology Group performed a Phase II trial of topotecan administered as a continuous infusion in adult patients with advanced soft tissue sarcomas.
  
  
  METHODS
  Patients who had received no prior chemotherapy for advanced disease were treated with topotecan at a dose of 0.50 mg/m2/day on days 1-21 of repeated 28 day cycles.
  
  
  RESULTS
  Twenty-two patients were enrolled on the study, of whom 21 were eligible. No objective responses were observed (95% confidence interval of 0-16%). The median survival was 12 months (95% confidence interval of 5-16 months).
  
  
  CONCLUSIONS
  We conclude that topotecan, given either according to a 5-day or a 21-day schedule, has minimal activity in the treatment of adult soft tissue sarcomas.
authors: Cleveland Clinic Foundation, OH, USA.
authors: G Thomas
authors: GT
authors: Budd
authors: Cathryn
authors: C
authors: Rankin
authors: Laura F
authors: LF
authors: Hutchins
authors: Lucas
authors: L
authors: Wong
authors: Paul J
authors: PJ
authors: Petruska
authors: Karen
authors: K
authors: Antman
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D019772:Topotecan / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan